JP2014502276A - アミロイドプラーク関連症状の治療のための組成物及び方法 - Google Patents

アミロイドプラーク関連症状の治療のための組成物及び方法 Download PDF

Info

Publication number
JP2014502276A
JP2014502276A JP2013542218A JP2013542218A JP2014502276A JP 2014502276 A JP2014502276 A JP 2014502276A JP 2013542218 A JP2013542218 A JP 2013542218A JP 2013542218 A JP2013542218 A JP 2013542218A JP 2014502276 A JP2014502276 A JP 2014502276A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
apoe
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013542218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502276A5 (https=
Inventor
デーヴィッド ホルツマン，
ジュンス キム，
ホン チァン，
アダム エルトライ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2014502276A publication Critical patent/JP2014502276A/ja
Publication of JP2014502276A5 publication Critical patent/JP2014502276A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2013542218A 2010-12-02 2011-12-02 アミロイドプラーク関連症状の治療のための組成物及び方法 Pending JP2014502276A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US61/419,060 2010-12-02
US201161548542P 2011-10-18 2011-10-18
US61/548,542 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (2)

Publication Number Publication Date
JP2014502276A true JP2014502276A (ja) 2014-01-30
JP2014502276A5 JP2014502276A5 (https=) 2015-01-22

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013542218A Pending JP2014502276A (ja) 2010-12-02 2011-12-02 アミロイドプラーク関連症状の治療のための組成物及び方法

Country Status (14)

Country Link
US (2) US20140037638A1 (https=)
EP (1) EP2646053A4 (https=)
JP (1) JP2014502276A (https=)
KR (1) KR20140017513A (https=)
CN (1) CN103338786A (https=)
AU (1) AU2011336360A1 (https=)
BR (1) BR112013013723A2 (https=)
CA (1) CA2819679A1 (https=)
MX (1) MX2013006116A (https=)
NZ (1) NZ611614A (https=)
RU (1) RU2013130002A (https=)
SG (1) SG190952A1 (https=)
WO (1) WO2012075422A2 (https=)
ZA (1) ZA201303996B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506162A (ja) * 2016-10-28 2020-02-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 抗ａｐｏｅ抗体

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US10830775B2 (en) 2014-09-30 2020-11-10 Washington University Tau kinetic measurements
WO2017192711A1 (en) * 2016-05-03 2017-11-09 University Of South Florida Compositions and methods of modulating abeta protein
WO2019018402A2 (en) * 2017-07-17 2019-01-24 Janssen Biotech, Inc. ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
CA3141988A1 (en) * 2019-05-28 2020-12-03 The General Hospital Corporation Apoe antibodies, fusion proteins and uses thereof
US20240400659A1 (en) * 2021-10-19 2024-12-05 Bioatla, Inc. Conditionally active proteins for neurodegenerative diseases
CN120787237A (zh) * 2022-11-30 2025-10-14 明尼苏达大学董事会 自然杀伤细胞接合剂
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502311A (ja) * 2003-11-28 2008-01-31 アストラゼネカ アーベー 抗体
JP2009531299A (ja) * 2006-02-21 2009-09-03 オクラホマ メディカル リサーチ ファウンデーション ＡｐｏＥ受容体へのＡｐｏＥの結合のインヒビターによるアルツハイマー病の処置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
WO2005094846A1 (ja) * 2004-03-30 2005-10-13 Renomedix Institute Inc. プリオン病治療剤およびその製造方法
JP5632582B2 (ja) * 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2011109246A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502311A (ja) * 2003-11-28 2008-01-31 アストラゼネカ アーベー 抗体
JP2009531299A (ja) * 2006-02-21 2009-09-03 オクラホマ メディカル リサーチ ファウンデーション ＡｐｏＥ受容体へのＡｐｏＥの結合のインヒビターによるアルツハイマー病の処置

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506162A (ja) * 2016-10-28 2020-02-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 抗ａｐｏｅ抗体
JP2022191397A (ja) * 2016-10-28 2022-12-27 ワシントン・ユニバーシティ 抗ａｐｏｅ抗体
JP7236737B2 (ja) 2016-10-28 2023-03-10 ワシントン・ユニバーシティ 抗ａｐｏｅ抗体

Also Published As

Publication number Publication date
AU2011336360A1 (en) 2013-07-04
KR20140017513A (ko) 2014-02-11
SG190952A1 (en) 2013-07-31
EP2646053A2 (en) 2013-10-09
RU2013130002A (ru) 2015-01-10
NZ611614A (en) 2015-07-31
US20160355581A1 (en) 2016-12-08
US20140037638A1 (en) 2014-02-06
ZA201303996B (en) 2015-10-28
BR112013013723A2 (pt) 2019-09-24
WO2012075422A3 (en) 2012-10-04
MX2013006116A (es) 2013-10-17
CA2819679A1 (en) 2012-06-07
CN103338786A (zh) 2013-10-02
WO2012075422A2 (en) 2012-06-07
EP2646053A4 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
JP2014502276A (ja) アミロイドプラーク関連症状の治療のための組成物及び方法
TWI789644B (zh) 抗－N3pGlu類澱粉β肽抗體及其用途
US12540175B2 (en) Anti-ApoE antibodies
AU2006319358B2 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
CN1426423B (zh) 螯合淀粉样蛋白β肽的人源化抗体
US20230416393A1 (en) Cd6 antibody for treatment of t-cell mediated diseases or disorders
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
CN112166121B (zh) 神经生长因子的单克隆抗体及其编码基因和应用
JP2001511369A (ja) 病理的状態に関連する斑および凝集物の蛋白成分の選択的な溶解用のプロテアーゼ活性を有する触媒性モノクローナル抗体
US20140127225A1 (en) Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
AU2023200728A1 (en) Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
WO2022132923A1 (en) Tau binding compounds
WO2021262564A1 (en) Use of semaphorin-4d binding molecules for the treatment of rett syndrome
WO2025119350A1 (zh) 靶向Tau的特异性结合蛋白及其应用
US20230090965A1 (en) Prophylactic or therapeutic agent for dementia
HK40005250A (en) Compositions and methods for treating spinal muscular atrophy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160913